Clinical Trials Browser

Interventional × HER2-positive Breast Cancer × Docetaxel × Clear all

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

HER2-positive Breast Cancer

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 3 Recruiting

HER2-positive Breast Cancer

NCT07377643 2026-02-25

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Phase 3 Recruiting

HER2-positive Breast Cancer

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Phase 3 Completed

HER2-positive Breast Cancer

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT06445400 2025-08-03

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase 2 Recruiting

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Phase 3 Completed

214 enrolled 16 charts

HER2-positive Breast Cancer

NCT05985187 2023-08-14

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase 3 Unknown

HER2-positive Breast Cancer

NCT05720026 2023-02-09

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

Phase 3 Unknown

HER2-positive Breast Cancer

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Phase 2/3 Unknown

HER2-positive Breast Cancer

NCT03238495 2021-12-07

HERMET

Phase 2 Unknown

HER2-positive Breast Cancer

NCT04034823 2019-07-26

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT02379585 2018-04-24

STEFNE

Phase 1/2 Terminated

8 enrolled 1 chart

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Phase 1/2 Terminated

4 enrolled 1 chart

HER2-positive Breast Cancer